An allogeneic cell therapy based on the expansion of a subpopulation of umbilical cord tissue mesenchymal cells (UC-MSCs), developed by Cells for Cells as an adjuvant for the treatment of Systemic Lupus Erythematosus (SLE)

Infused intravenously in patients with severe renal lupus.

Phase I-IIa clinical study successfully completed.

A new phase IIb controlled clinical study is aimed at comparing the results of conventional treatments, depending on whether or not an intravenous injection of umbilical cord MSCs is added as a co-treatment of the disease. If a significant therapeutic effect is corroborated, this advanced therapy from Cells for Cells could become a very important adjuvant for the treatment of SLE without a general immunosuppressive effect and suitable for the treatment of patients with severe forms that are usually very difficult to treat.


Technology Readiness Level (TRL)